USP8 Mutations and Cell Cycle Regulation in Corticotroph Adenomas

Abstract

Corticotroph adenomas frequently harbor somatic USP8 mutations. These adenomas also commonly exhibit underexpression of P27, a cell cycle regulator. The present study aimed to determine the influence of USP8 mutations on clinical features of Cushingʼs disease and to elucidate the relationship between USP8 mutations and P27 underexpression in these tumors. Retrospective study with 32 patients with Cushingʼs disease was followed at the Ribeirao Preto Medical School University Hospital. We evaluated the patientsʼ clinical data, the USP8 mutation status and the gene expression of cell cycle regulators P27/CDKN1B, CCNE1, CCND1, CDK2, CDK4, and CDK6 in tumor tissue in addition to the protein expression of P27/CDKN1B. We observed somatic mutations in the exon 14 of USP8 in 31.3% of the patients. Larger tumor size was observed in patients harboring USP8 mutations (p=0.04), with similar rates of remission, age of presentation, salivary cortisol at 23:00 h and after 1 mg dexamethasone, ACTH levels, and early postoperative plasma cortisol. We observed no differences regarding the gene or protein expression of the cell cycle regulators according to USP8 mutation status. In this Brazilian series, the observed frequency of USP8 somatic mutations was similar to that reported in European ancestry populations. Although it was reasonable that USP8 mutations could contribute to cell cycle dysregulation and P27 underexpression in corticotroph adenomas, our data did not confirm this hypothesis. It is possible that increased deubiquitinase activity observed in mutated USP8 might influence other pathways related to cell growth and proliferation.

Key words

pituitary ACTH hypersecretion - pituitary neoplasms - cell cycle - USP8 protein - cyclin-dependent kinase inhibitor p27

• References

• 1 Quereda V, Malumbres M. Cell cycle control of pituitary development and disease. J Mol Endocrinol 2009; 42: 75-86
• 2 Nakayama K, Ishida N, Shirane M. et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707-720
• 3 Pellegata NS, Quintanilla-Martinez L, Siggelkow H. et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006; 103: 15558-15563
• 4 Simpson DJ, Frost SJ, Bicknell JE. et al. Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 2001; 22: 1149-1154
• 5 Jin L, Qian X, Kulig E. et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 1997; 151: 509-519
• 6 Lidhar K, Korbonits M, Jordan S. et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999; 84: 3823-3830
• 7 Bamberger CM, Fehn M, Bamberger AM. et al. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol 1999; 140: 250-255
• 8 Lloyd RV, Jin L, Qian X. et al. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 1997; 150: 401-407
• 9 Dahia PL, Aguiar RC, Honegger J. et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 1998; 16: 69-76
• 10 Tanaka C, Yoshimoto K, Yang P. et al. Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. J Clin Endocrinol Metab 1997; 82: 3141-3147
• 11 Takeuchi S, Koeffler HP, Hinton DR. et al. Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. J Endocrinol 1998; 157: 337-341
• 12 Yoshino A, Katayama Y, Ogino A. et al. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. J Neurooncol 2007; 83: 153-162
• 13 Martins CS, Camargo RC, Saggioro FP. et al. P27/CDKN1B translational regulators in pituitary tumorigenesis. Horm Metab Res 2016; 48: 840-846
• 14 Musat M, Korbonits M, Pyle M. et al. The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors. Pituitary 2002; 5: 235-242
• 15 Liu W, Asa SL, Ezzat S. Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells. Brain Pathol 2002; 12: 412-419
• 16 Korbonits M, Chahal HS, Kaltsas G. et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002; 87: 2635-2643
• 17 Musat M, Korbonits M, Kola B. et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 2005; 12: 423-433
• 18 Roussel-Gervais A, Couture C, Langlais D. et al. The Cables1 gene in glucocorticoid regulation of pituitary corticotrope growth and cushing disease. J Clin Endocrinol Metab 2016; 101: 513-522
• 19 Hernandez-Ramirez LC, Gam R, Valdes N. et al. Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushingʼs disease. Endocr Relat Cancer 2017; 24: 379-392
• 20 Reincke M, Sbiera S, Hayakawa A. et al. Mutations in the deubiquitinase gene USP8 cause Cushingʼs disease. Nat Genet 2015; 47: 31-38
• 21 Ma ZY, Song ZJ, Chen JH. et al. Recurrent gain-of-function USP8 mutations in Cushingʼs disease. Cell Res 2015; 25: 306-317
• 22 Chen J, Jian X, Deng S. et al. Identification of recurrent USP48 and BRAF mutations in Cushingʼs disease. Nat Commun 2018; 9: 3171
• 23 Mizuno E, Iura T, Mukai A. et al. Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes. Mol Biol Cell 2005; 16: 5163-5174
• 24 Theodoropoulou M, Arzberger T, Gruebler Y. et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: Evidence for a role in corticotropinoma cells. J Endocrinol 2004; 183: 385-394
• 25 Fukuoka H, Cooper O, Ben-Shlomo A. et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 2011; 121: 4712-4721
• 26 Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992; 9: 383-391
• 27 Wang J, Barnes RO, West NR. et al. Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer. Breast Cancer Res 2008; 10: R51
• 28 Pedroza-Saavedra A, Lam EW, Esquivel-Guadarrama F. et al. The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27(Kip1). Virology 2010; 400: 44-52
• 29 Nieman LK, Biller BM, Findling JW. et al. The diagnosis of Cushingʼs syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
• 30 Castro M, Elias PC, Quidute AR. et al. Out-patient screening for Cushingʼs syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 1999; 84: 878-882
• 31 Elias PC, Martinez EZ, Barone BF. et al. Late-night salivary cortisol has a better performance than urinary free cortisol in the diagnosis of Cushingʼs syndrome. J Clin Endocrinol Metab 2014; 99: 2045-2051
• 32 Bertagna X, Guignat L, Groussin L. et al. Cushingʼs disease. Best Pract Res Clin Endocrinol Metab 2009; 23: 607-623
• 33 Arnaldi G, Angeli A, Atkinson AB. et al. Diagnosis and complications of Cushingʼs syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-5602
• 34 Perez-Rivas LG, Theodoropoulou M, Ferrau F. et al. The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing cushingʼs disease. J Clin Endocrinol Metab 2015; 100: E997-E1004
• 35 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408
• 36 Storr HL, Alexandraki KI, Martin L. et al. Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between paediatric and adult-onset Cushingʼs disease. Eur J Endocrinol 2011; 164: 667-674
• 37 Hayashi K, Inoshita N, Kawaguchi K. et al. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushingʼs disease. Eur J Endocrinol 2016; 174: 213-226
• 38 Faucz FR, Tirosh A, Tatsi C. et al. Somatic USP8 gene mutations are a common cause of pediatric cushing disease. J Clin Endocrinol Metab 2017; 102: 2836-2843
• 39 Souza MC, Martins CS, Silva-Junior IM. et al. NR3C1 polymorphisms in Brazilians of Caucasian, African, and Asian ancestry: Glucocorticoid sensitivity and genotype association. Arq Bras Endocrinol Metabol 2014; 58: 53-61
• 40 Zilio M, Barbot M, Ceccato F. et al. Diagnosis and complications of Cushingʼs disease: Gender-related differences. Clin Endocrinol (Oxf) 2014; 80: 403-410
• 41 Jian FF, Li YF, Chen YF. et al. Inhibition of ubiquitin-specific peptidase 8 suppresses adrenocorticotropic hormone production and tumorous corticotroph cell growth in AtT20 Cells. Chin Med J (Engl) 2016; 129: 2102-2108
• 42 Ballmann C, Thiel A, Korah HE. et al. USP8 mutations in pituitary cushing adenomas-targeted analysis by next-generation sequencing. J Endocr Soc 2018; 2: 266-278
• 43 Theodoropoulou M, Reincke M, Fassnacht M. et al. Decoding the genetic basis of Cushingʼs disease: USP8 in the spotlight. Eur J Endocrinol 2015; 173: M73-M83